Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pretty sure I asked you about this but you never gave a response.
Point out on the clinical trial.gov website where the current CEO (Lalezari) served as Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche.
Please, no idiotic mumbo jumbo which you 14 cent per share dupes are famous for, just answer the fucking question.
Um, mr (see my profile pic), bankruptcy statements based on--- Since our inception, we have been insolvent and have required debt and equity financing to maintain operations. We expect our debt service obligations and our need for additional funding to finance operations will cause additional substantial dilution to our existing stockholders and could adversely affect the trading price of our common stock. https://www.sec.gov/Archives/edgar/data/1175680/000155837023015718/cydy-20230531x10k.htm
Winding down statement based on--- On April 3, 2024, CytoDyn Inc. (the “Company”) and Samsung BioLogics Co., Ltd. (“Samsung”) executed an agreement (the “Letter Agreement”), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the “Total Balance”). The Letter Agreement resolves the Company’s obligations under the Master Services Agreement and related ancillary agreements first entered into between Samsung and the Company in or around April 2019 (collectively, the “Agreement”). https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/cydy-20240403x8k.htm
The above is definitely a provision for payment of the debts and other liabilities of the Company---
3. Liquidation. Upon the dissolution, liquidation or winding up of the Company, after payment or provision for payment of the debts and other liabilities of the Company and subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Company upon such dissolution, liquidation or winding up of the Company, the holders of Common Stock shall be entitled to receive the remaining assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held by them. https://www.sec.gov/Archives/edgar/data/1175680/000155837024000836/cydy-20240130xex3d1.htm
All *their* words, not mine or anyone elses.
GIVING FINANCIAL ADVICE--- Thats just *your* ignorant interpretation....in reality its the SEC filings, PRs, conference calls, etc, that are giving the financial advice...parroting exactly what the published filings, PRs, and etc say is not giving financial advice.
You *confirmed* dumbass losers need to find another scapegoat for your ignorant investment decisions.
So name the LIES dumdum...wait, you cant or you already wouldve.
Um, mr (see my profile pic), stop lying. The key ingredient to "manipulation" is dissemination of misinformation (lying).
Since all the "bashing" on this message board is derived directly from SEC filings, PRs, conference calls, etc, point out exactly which lies have manipulated this stock to 15 cents.
Yes kgro, anything to distract the FACT that Mitch has started the winding up process.
Lets see pumpers post the DOJ emails to CYDY regarding Securities and Exchange Commission and Department of Justice Investigations---
The Company has received subpoenas from the SEC and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain former Company executives and directors have received subpoenas concerning similar issues and have been interviewed by the DOJ and SEC, including the Company’s former CEO, Nader Z. Pourhassan. https://www.sec.gov/Archives/edgar/data/1175680/000155837024000305/cydy-20231130x10q.htm
Roger that TDK. Not only that but this quote in particular reads like a last will and testament--- and will be transitioning the aforementioned services to one, or several, of its CURRENT SERVICE PROVIDERS
Yup. Looks like Mitch is shifting the plan into gear...its over.
Um fish, nothing "boilerplate" about it...Mitch is doing exactly what folks here initially rumored him to do.
Its happening..."winding down" now all of a sudden a reality with Samsung being the first shoe to drop.
3. Liquidation. Upon the dissolution, liquidation or winding up of the Company, after payment or provision for payment of the debts and other liabilities of the Company and subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Company upon such dissolution, liquidation or winding up of the Company, the holders of Common Stock shall be entitled to receive the remaining assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held by them. https://www.sec.gov/edgar/search/?r=el#/q=winding&page=1&ciks=0001175680&entityName=CytoDyn%2520Inc.%2520%2520(CIK%25200001175680)&category=form-cat0&forms=-3%252C%2520-4%252C%2520-5&sort=desc
Speaking of results, where exactly can the 82% nonsense youve been yodeling for years be found on the clinical trials.gov website?
Please point that out with link included.
I found the Principal Investigator list so why didnt CYDY want to divulge a designated PI on the main Study page?---
Contacts/Locations Central Contact Person Name Kush Dhody, MBBS, MS, CCRA Telephone 301-956-2536 Email kushd@amarexcro.com Study Officials
Location Alexander City, Alabama, United States, 35010 Status: Recruiting Facility: Advanced Cardiovascular, LLC Contact: Contact Sabrina Forbus, RN, BSN 256-215-5323 Principal Investigator William Ross Davis, MD Fullerton, California, United States, 92835 Status: Recruiting Facility: St. Jude Medical Center Contact: Contact Blanca Sanchez 714-446-5620 Blanca.Sanchez@stjoe.org Principal Investigator David J Park, MD Los Angeles, California, United States, 90095 Status: Recruiting Facility: UCLA Contact: Contact Nancy Lopez 310-794-8043 NancyRLopez@mednet.ucla.edu Principal Investigator Otto Yang, MD Tampa, Florida, United States, 33612 Status: Recruiting Facility: James A. Haley Veterans' Hospital Contact: Contact Adam Zoble 813-631-3671 Adam.Zoble@va.gov Principal Investigator Koushik Reddy, MD Gainesville, Georgia, United States, 30501 Status: Active, not recruiting Facility: Center for Advanced Research & Education (CARE) Boston, Massachusetts, United States, 02215 Status: Recruiting Facility: Beth Israel Deaconess Medical Center Contact: Contact Caitlin Davis 617-735-4466 Cdavis6@bidmc.harvard.edu Principal Investigator Sabrina Tan, MD Livingston, New Jersey, United States, 07052 Status: Recruiting Facility: St. Barnabas Contact: Principal Investigator Subroto Paul, MD Morristown, New Jersey, United States, 07962-1905 Status: Recruiting Facility: Atlantic Health System Hospital Contact: Principal Investigator Eric Whitman, MD Teaneck, New Jersey, United States, 07666 Status: Recruiting Facility: Holy Name Medical Center Contact: Contact Patty Kiledjian 201-541-6312 pkiledjian@holyname.org Principal Investigator Benjamin De La Rosa, MD Bronx, New York, United States, 10467 Status: Recruiting Facility: Montefiore Medical Center Contact: Contact Jane Wilson 718-920-7916 Principal Investigator Harish Seethamraju, MD Brooklyn, New York, United States, 11229 Status: Recruiting Facility: New York Community Hospital of Brooklyn Contact: Contact Marina Bilik 718-692-5336 mbilik@nych.com Principal Investigator Isaia Avraham, MD Winston-Salem, North Carolina, United States, 27103 Status: Recruiting Facility: Novant Health Contact: Contact Shannon Bowman shannon.bowman@novanthealth.org Contact Pailing Richards 704-996-7627 pcrichards@novanthealth.org Principal Investigator Michael Morgan, MD Columbus, Ohio, United States, 43215 Status: Recruiting Facility: Ohio Health Contact: Principal Investigator Kiran Devulapally, MD Corvallis, Oregon, United States, 97330 Status: Recruiting Facility: Good Samaritan Hospital Corvallis Contact: Contact Stephanie Mock 541-768-4352 stmock@samhealth.org Principal Investigator Brian Delmonaco, MD Portland, Oregon, United States, 97239 Status: Recruiting Facility: Oregon Health and Sciences University Contact: Principal Investigator Marcel Curlin, MD Dallas, Texas, United States, 75204 Status: Recruiting Facility: Baylor Scott & White Research Institute Contact: Contact Samantha Wang Samantha.wang@bswhealth.org Principal Investigator Uriel Sandkovsky Houston, Texas, United States, 77030 Status: Recruiting Facility: Baylor College of Medicine Contact: Contact Hinali Zaveri, MD 713-873-2353 hzaveri@bcm.edu Principal Investigator Kalpalatha Guntupalli, MD Houston, Texas, United States, 77030 Status: Recruiting Facility: University of Texas Contact: Contact Jordan Lake 713-500-6767 Jordan.e.lake@uth.tmc.edu Principal Investigator Jordan Lake, MD https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8&tab=history&a=13#contacts-locations-card
Hmmm, 18 Study Locations and not one single Principal Investigator listed right? RIGHT?
United States Alabama Locations Alexander City, Alabama, United States, 35010 Advanced Cardiovascular, LLC California Locations Fullerton, California, United States, 92835 St. Jude Medical Center Los Angeles, California, United States, 90095 UCLA Florida Locations Tampa, Florida, United States, 33612 James A. Haley Veterans' Hospital Georgia Locations Gainesville, Georgia, United States, 30501 Center for Advanced Research & Education (CARE) Massachusetts Locations Boston, Massachusetts, United States, 02215 Beth Israel Deaconess Medical Center New Jersey Locations Livingston, New Jersey, United States, 07052 St. Barnabas Morristown, New Jersey, United States, 07962-1905 Atlantic Health System Hospital Teaneck, New Jersey, United States, 07666 Holy Name Medical Center New York Locations Bronx, New York, United States, 10467 Montefiore Medical Center Brooklyn, New York, United States, 11229 New York Community Hospital of Brooklyn North Carolina Locations Winston-Salem, North Carolina, United States, 27103 Novant Health Ohio Locations Columbus, Ohio, United States, 43215 Ohio Health Oregon Locations Corvallis, Oregon, United States, 97330 Good Samaritan Hospital Corvallis Portland, Oregon, United States, 97239 Oregon Health and Sciences University Texas Locations Dallas, Texas, United States, 75204 Baylor Scott & White Research Institute Houston, Texas, United States, 77030 Baylor College of Medicine Houston, Texas, United States, 77030 University of Texas https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8
And misiu, just one more thing, says here in that same study under the Researcher Tab"Information provided by CytoDyn, Inc." with no other independent person/entity that would attach their name to the data---
Yep, misius grubby little fingerprints are all over the article...case in point with the 2nd sentence in the 1st paragraph--- Proven means their drug reduced 14 day mortality by 82% in a phase 3 clinical trial.
Speaking of What was true , and what was a manipulation of security with lies .., you admitted on this forum it was *you* this article referenced but in the article not one single word about disclosing being invested in this stock.
Looks like a crime of manipulation of a security has occurred, just sayin.
Not only that, the article author makes use of the word "PROVEN" ("Proven means their drug reduced 14 day mortality by 82% in a phase 3 clinical trial.") which the FDA DEBUNKED as data dredged nonsense---
Leronlimab Anecdotes - A Patient's Perspective - Beating the System BY CHESSMASTER THURSDAY, AUG 12, 2021 - 22:03 CytoDyn, appears to be the only biotech company with a proven treatment in a large randomized controlled trial for severe and critical COVID-19. Proven means their drug reduced 14 day mortality by 82% in a phase 3 clinical trial. Proven doesn't mean the drug is approved by the FDA because they asked for more data. This is the rub because it's proven, but not approved and because of that the company has been under constant assault and criticism for how the management team has been handling the clinical trials. Their leading drug candidate is called leronlimab and is branded as Vyrologix and it has single handedly taken dying from COVID-19 off the table. Many of the critics of the Company are shareholders and in one special case a group of shareholders that called themselves Advancing Leronlimab and used what the Company described and illegal tactics to challenge the board of directors. Luckily for patients around the world their bid for greed and avarice failed.
When you put aside the greed and take a hard look at the company, their mission statement is to save lives and of course maximize shareholder value. This management team may be tiny in comparison to most biotechs, but enormous in terms of heart. This team actually cares for patients personally and at one time in the pandemic had the largest number of compassionate use approvals. The truth is that there’s only one reason for breaking a record for compassionate use and it has to do with the viability of the treatment. Many that have gotten either compassionate use or the rarely used Right to Try approvals have interfaced with top management as they worked tirelessly to get the approvals processed as quickly as possible.
Shareholders that have a hard time understanding how a drug with so much potential isn't approved by now don't understand how challenging the drug development process is, and they certainly don’t understand a management that seems to put patients’ lives first. At CytoDyn the CEO has gotten himself personally involved in pushing the process of many Emergency IND’s and compassionate use requests. This is not a normal thing that people are likely to see at any other biotech on the globe. The corporate culture really values human life and seems to do anything they can to preserve it.
Leronlimab has saved many lives. A very recent anecdotal report of another life saved by leronlimab underscores the importance of how truly revolutionary this drug could become. In order to preserve the privacy of the patient no identifying details will be used. Approximately 2 weeks ago a mother in the medical field was talking to her grown son who is also in the medical field and noticed over the phone that he sounded sick and nasally. The son indicated that he just had a bad cold and that something was going around because he thought since all people were all wearing masks for so long that their natural immunity was compromised and colds were on the rise. The mom was skeptical of the answer and made him take a home covid test from the pharmacy. Although he tested positive, the mom was well versed in treatment options and was prepared. She pumped him up with ivermectin, vitamins and eventually resorted to hydroxychloroquine. Nothing seemed to work, and after a couple of days his oxygen levels eventually dropped into the mid 70’s forcing him to call an ambulance. When he arrived he found himself in an unfortunate situation. The Floridian healthcare system was experiencing a surge and was overrun with patients. After many hours of waiting he was diagnosed via a chest X ray having double lobe pneumonia, no treatment was administered and the son found his way back home after picking up a canister of oxygen to use at home. During his wait in the Emergency room he was not provided water, or intravenous fluids, or a bed to lay down on. Despite his use of oxygen at home his oxygen levels continued to deteriorate to 74%. He could barely breathe or talk. This put him at severe risk of dying, he needed to get back to the hospital. The surrounding hospitals were all full capacity so the resourceful mom called around looking for open beds. Eventually he was admitted to another hospital with a compassionate doctor leading the treatment. The first treatment offered was Remdesivir and that was patently rejected by the mom who read the reports and understood it was not appropriate for her son's situation. This was a cytokine storm not a viral infection. She made it known that she wanted leronlimab to be used for her son. Instead of saying no, the doctor suggested they try one of the approved options like tocilizumab first and see if there was any change before they go the Right to Try route. After 3 days of seeing continued deterioration the Right to Try paperwork was signed by the doctor. The drug made it to the hospital the very next day. This was very A-typical because the mom was completely prepared and was on top of the communication.
Before taking leronlimab the patient was on high flow oxygen consuming between 6 – 10 liters. Since leronlimab is a subcutaneous shot it takes time to enter the bloodstream and she cautioned her son to remain patient. After administration it took two hours before there was a change in his status. The patient was able to talk better and had a more productive cough and the oxygen saturation levels started to increase. After 4-5 hours oxygen levels improves so much high flow oxygen was removed and reduced to the nasal cannula. The patient's strength was coming back and he felt like leaving the hospital, but there was also pressure for him to leave to make room for the sick that were in the hallways. The patient was ultimately discharged 26 hours after being injected with leronlimab, and went home with instructions to use oxygen as needed and report back if there was a worsening of conditions.
All these anecdotal patients that took leronlimab, which numbers over 100 understand one truth. The drug works and works extremely well and in most cases quickly. The last thing these patients care about is the greed involved in developing a drug and the he said she said minutia in the boardroom. They welcome a CEO and a company with a refreshing attitude that just wants to save lives. Critically ill patients have been abandoned by both the FDA with their draconian policies and politicians whom seem to be more concerned about mandating vaccines and masks. Team CytoDyn and Hero moms need to be celebrated whenever possible.
The measures to curb the pandemic failed with over 620,000 American in body bags. Initial estimates were 200,000. History will eventually reflect upon how many lives that could have been saved if leronlimab was approved sooner. There is still a long approval road ahead for leronlimab in the United States, but Brazil has their own pivotal trial starting imminently and may be the first beneficiary of a COVID drug that takes dying off the table and flattens the curve.
The situation in Florida with respect to available ICU beds is really bad and here sits a drug that saves the lives of almost everyone it touches. It also has the potential to seriously flatten the curve in hard hit areas because if all the people sitting in the hallways were given this very safe drug they might actually go home like this patient did. People need to know about this drug and the process required to get it. Right now it's only available via Right to Try since it doesn't have its EUA approval or any active clinical trial sites in the USA. Eventually the FDA will come around to approving this drug but in the meantime it's pointless to provoke the FDA and try to force an approval. That's been tried before and has failed. People just need to work within the system to get the drug for your loved ones should they need it. The hero mom in this story was well educated and prepared on what to do in case of this eventuality. Advanced preparedness seems to be partly responsible for the happy ending. So the lesson learned here is that there is no substitute for preparation. It's clear that this drug takes dying off the table and when politicians decide they've seen enough body bags then maybe this drug will see the light of day for use in COVID-19 in the United States.
Right to Try is the only way to access leronlimab and take dying off the table for severe to critical patients. The only hitch is that you have to ask for it and you have to get a doctor at the hospital willing to step up. These anecdotal reports are just whispers right now, but they will turn into a thunderous call to action as the pandemic worsens and news of the drugs success continues to spread.
1. We note statements in your proposed disclosure for Item 1 and Note 4 that you believe leronlimab is safe and effective, as well as language implying the existence of “clinical data that supports its safety and efficacy.” As safety and efficacy determinations are within the authority of the U.S. Food and Drug Administration and comparable regulatory bodies, please revise your proposed disclosure to remove language that states or implies that you believe leronlimab is safe and effective or that leronlimab is likely to be found safe and effective. You may contact Jeanne Baker at 202-551-3691 or Terence O'Brien, Branch Chief, at 202-551-3355 if you have questions. https://www.sec.gov/Archives/edgar/data/1175680/000000000021006508/filename1.pdf
(sigh) Another liar weighs in--- Case in point, telling the lie you never will never sell a share under $40.
Need the link?
Speaking of links, you never post any DD, always yodeling from the peanut gallery you goddam proverbial Nutbush TN or MS simpleton that dosent know how to use 'your' and 'you're'...need those links?
Go ahead and say your world famous line..."oooh you sound mad", and then move on to your next no DD dumbass comments.
News 
Market Data 
Discover 
AI
